Multiple Myeloma Clinical Trial
Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
The purpose of this study is to study taste disturbances on patients with myeloma who received high dose melphalan.
Age 21 or above with diagnosis of multiple myeloma (myeloma is almost unheard of in patients less than 21 years of age).
Scheduled to receive conditioning chemotherapy with melphalan followed by upfront or salvage autologous peripheral blood hematopoietic stem cell transplantation
English or Spanish speaking
Calculated creatinine clearance > 40 mL/min
Prior head and neck radiation.
Severe periodontal infection. Poor oral hygiene and dentition as determined by pre HCT dental assessment.
Patients with pre-existing moderate-severe dysgeusia
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10021, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.